SMC1A and colorectal carcinoma: Indeed, SMC1A mutations have been identified in CRC [26, 27] whereas overexpression of the protein has been found in advanced diseases and is associated with a poor prognosis [28, 29], suggesting that inhibition of SMC1A may serve as a promising therapeutic strategy for human CRC.